Search results
Results from the WOW.Com Content Network
It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week ...
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...
For premium support please call: 800-290-4726 more ways to reach us
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...